https://mindmedicinelaw.com/briefing/filament-health-s-psilocybin-supply-deal-implications-for-research-and-market-20260825-35608The Psychedelic Journalen2026-08-25T22:05:12.472559+00:00Filament Health's Psilocybin Supply Deal: Implications for Research and Marketfilament health, psilocybin supply, PEX01, psychedelic research, clinical trials, market access, therapeutic use, regulatory implications, mental health treatment, psychedelic compoundshttps://mindmedicinelaw.com/briefing/uw-s-psilocybin-retreats-for-cancer-clinical-trial-insights-20260825-35607The Psychedelic Journalen2026-08-25T22:04:45.678542+00:00UW's Psilocybin Retreats for Cancer: Clinical Trial Insightspsilocybin retreats, advanced cancer, palliative care, psychedelic therapies, clinical trial, University of Washington, mental health benefits, FDA regulations, group therapy, serotonin receptorshttps://mindmedicinelaw.com/briefing/rhelion-life-sciences-psilocybin-supply-deal-with-uw-20260825-35453The Psychedelic Journalen2026-08-25T15:05:43.217830+00:00Rhelion Life Sciences' Psilocybin Supply Deal with UWpsilocybin research, Rhelion Life Sciences, University of Washington, clinical trials, psychedelic therapies, mental health treatment, regulatory implications, biotech partnershipshttps://mindmedicinelaw.com/briefing/oregon-s-psychedelic-dataset-outpaces-historical-trials-20260825-35452The Psychedelic Journalen2026-08-25T15:04:44.499541+00:00Oregon's Psychedelic Dataset Outpaces Historical TrialsOregon psychedelic dataset, state-level data, federal regulators, psilocybin therapy, clinical trials, policy implications, data integration, psychedelic research, public health, therapeutic applicationshttps://mindmedicinelaw.com/briefing/fda-accelerates-psychedelic-approvals-urges-washington-action-20260824-35606The Psychedelic Journalen2026-08-25T22:04:59.816412+00:00FDA Accelerates Psychedelic Approvals, Urges Washington ActionFDA, psychedelic therapies, drug approval, clinical trials, mental health, legislative action, policy changes, market dynamics, research funding, Controlled Substances Acthttps://mindmedicinelaw.com/briefing/bmi-s-influence-on-depression-treatment-outcomes-20260824-35383The Psychedelic Journalen2026-08-25T15:05:58.306201+00:00BMI's Influence on Depression Treatment OutcomesBMI, treatment-resistant depression, systematic review, personalized medicine, pharmacotherapy, ketamine, transcranial magnetic stimulationhttps://mindmedicinelaw.com/briefing/cmps-stock-surge-implications-for-fda-psychedelic-review-20260824-35451The Psychedelic Journalen2026-08-25T15:05:25.320258+00:00CMPS Stock Surge: Implications for FDA Psychedelic ReviewCMPS stock, FDA hearing, psychedelic therapies, regulatory pathways, market dynamics, drug approval process, psilocybin research, investor confidence, mental health treatment, clinical trialshttps://mindmedicinelaw.com/briefing/ketamine-s-opioid-nature-implications-for-regulation-and-therapy-20260824-35444The Psychedelic Journalen2026-08-25T15:04:58.010610+00:00Ketamine's Opioid Nature: Implications for Regulation and Therapyketamine, opioid receptors, pharmacodynamics, mental health treatment, regulatory classification, clinical guidelineshttps://mindmedicinelaw.com/briefing/psilocybin-regulation-and-use-in-oregon-current-status-20260824-35337The Psychedelic Journalen2026-08-24T22:04:11.149360+00:00Psilocybin Regulation and Use in Oregon: Current Statuspsilocybin legalization, Oregon psilocybin regulation, psychedelic therapy, psilocybin policy, therapeutic psilocybin, psilocybin community impact, psilocybin research, psilocybin risks, psilocybin integration services, Oregon Health Authorityhttps://mindmedicinelaw.com/briefing/psilocybin-s-clinical-viability-faces-critical-challenges-20260824-35182The Psychedelic Journalen2026-08-24T15:05:18.251321+00:00Psilocybin's Clinical Viability Faces Critical Challengespsilocybin clinical trials, psychedelic therapy, mental health treatment, FDA regulations, serotonin receptors, psychedelic industry, therapeutic potential, clinical efficacy, regulatory challenges, psilocybin riskshttps://mindmedicinelaw.com/briefing/mdma-n-acylethanolamines-patent-implications-for-ptsd-treatment-20260824-35183The Psychedelic Journalen2026-08-24T15:05:05.828975+00:00MDMA-N-Acylethanolamines Patent: Implications for PTSD TreatmentMDMA-N-Acylethanolamines, PTSD treatment, psychedelic therapies, patent application, clinical trials, psychedelic industryhttps://mindmedicinelaw.com/briefing/neurothera-clearmind-s-mdma-ptsd-treatment-ip-gains-momentum-20260824-35181The Psychedelic Journalen2026-08-24T15:04:14.893965+00:00NeuroThera-Clearmind's MDMA-PTSD Treatment IP Gains MomentumMDMA, PTSD treatment, NeuroThera, Clearmind, psychedelic research, federal support, clinical trials, N-acylethanolamines, psychedelic therapies, market dynamicshttps://mindmedicinelaw.com/briefing/trait-responsiveness-and-placebo-effects-in-psychedelic-trials-20260823-35370The Psychedelic Journalen2026-08-25T15:06:09.365278+00:00Trait Responsiveness and Placebo Effects in Psychedelic Trialstrait responsiveness, placebo effects, psychedelic research, clinical trials, verbal suggestions, meta-analysishttps://mindmedicinelaw.com/briefing/triptally-analyzing-psychedelic-therapy-costs-with-open-access-tool-20260821-35103The Psychedelic Journalen2026-08-24T15:04:28.346038+00:00TripTally: Analyzing Psychedelic Therapy Costs with Open-Access Toolpsychedelic therapy, TripTally, cost calculator, economic modeling, labor costs, FDA approval, healthcare integration, therapy delivery models, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/reevaluating-psychedelic-trial-designs-challenges-and-solutions-20260820-35106The Psychedelic Journalen2026-08-24T15:04:41.418953+00:00Reevaluating Psychedelic Trial Designs: Challenges and Solutionspsychedelic trials, clinical trial design, pretreatment expectancy, double-blind procedure, causal identification, alternative trial designs, psychedelic therapy, research methodology, ethical considerationshttps://mindmedicinelaw.com/briefing/oregon-psilocybin-services-show-long-term-benefits-20260819-35454The Psychedelic Journalen2026-08-25T15:05:11.526441+00:00Oregon Psilocybin Services Show Long-Term Benefitspsilocybin therapy, Oregon psilocybin services, mental health treatment, psychedelic research, public health policy, clinical trials, long-term benefits, serotonin receptors, psychedelic therapy, mental health outcomeshttps://mindmedicinelaw.com/briefing/psilocybin-use-in-older-adults-new-insights-and-implications-20260818-35075The Psychedelic Journalen2026-08-24T15:04:54.082654+00:00Psilocybin Use in Older Adults: New Insights and Implicationspsilocybin, older adults, psychedelic research, state-regulated services, mental health, end-of-life care, clinical trials, therapeutic interventions, safety, efficacy